<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03351816</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A00731-52</org_study_id>
    <nct_id>NCT03351816</nct_id>
  </id_info>
  <brief_title>Impact of New Biomarkers on Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation</brief_title>
  <acronym>Biorhythm</acronym>
  <official_title>Impact of New Biomarkers on the Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Biorhythm study aims to investigate the utility of new biomarkers (e.g. MR proANP, ST2)&#xD;
      measured pre-procedure for the prediction of procedural success in patients with atrial&#xD;
      fibrillation undergoing cardioversion or ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, multicentre study of patients with paroxystic or&#xD;
      persistent atrial fibrillation scheduled to undergo cardioversion or ablation of AF in&#xD;
      routine practice. Serum levels of MR proANP and ST2 pre-procedure will be measured to attempt&#xD;
      to identify a threshold that carries prognostic value for procedural success (maintenance of&#xD;
      sinus rhythm at one year).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent atrial tachycardia</measure>
    <time_frame>12 months</time_frame>
    <description>Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent flutter</measure>
    <time_frame>12 months</time_frame>
    <description>Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent atrial fibrillation</measure>
    <time_frame>3 months</time_frame>
    <description>Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent atrial tachycardia</measure>
    <time_frame>3 months</time_frame>
    <description>Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent flutter</measure>
    <time_frame>3 months</time_frame>
    <description>Documented by ECG, Holter, telemetry, and lasting 30 seconds or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palpitations</measure>
    <time_frame>12 months</time_frame>
    <description>Any episode of palpitation occurring during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Hospital admission related to atrial fibrillation, atrial tachycardia or flutter during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat ablation</measure>
    <time_frame>12 months</time_frame>
    <description>Need for repeat ablation during follow-up in patients who underwent ablation of AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioversion</measure>
    <time_frame>12 months</time_frame>
    <description>Need for electric or medical cardioversion during follow-up (all patients, regardless of initial intervention type)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cardioversion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation of atrial fibrillation</intervention_name>
    <description>Pulmonary vein isolation by radiofrequency or cryoablation.</description>
    <arm_group_label>Ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardioversion</intervention_name>
    <description>External electric shock delivery under general anesthesia.</description>
    <arm_group_label>Cardioversion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with paroxystic or persistent atrial fibrillation for whom a decision to&#xD;
             perform ablation is made.&#xD;
&#xD;
          -  Patients with persistent atrial fibrillation for whom a decision to perform&#xD;
             cardioversion is made.&#xD;
&#xD;
          -  Patients with social security coverage, or beneficiary thereof.&#xD;
&#xD;
          -  Patients who provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years or &gt;80 years&#xD;
&#xD;
          -  Patients with significant valvular heart disease defined as symptomatic aortic valve&#xD;
             disease, severe aortic or mitral stenosis or tricuspid or mitral insufficiency grade&#xD;
             3/4 or 4/4&#xD;
&#xD;
          -  Patients with pulmonary arterial hypertension &gt;45 mmHg on echocardiography&#xD;
&#xD;
          -  Patients with chronic respiratory disease, chronic obstructive pulmonary disease stage&#xD;
             II, III or IV.&#xD;
&#xD;
          -  Patients with a left ventricular ejection fraction &lt;45%&#xD;
&#xD;
          -  Patients with recent (&lt;1 month) acute decompensation of heart failure&#xD;
&#xD;
          -  Patients with recent (&lt;1 month) acute coronary syndrome&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;10 g/dL)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Patients with anticipated poor compliance, as assessed by the study investigator&#xD;
&#xD;
          -  Patients within the exclusion period of another clinical study&#xD;
&#xD;
          -  Patients under legal guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Meneveau, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Fran√ßois Mitterand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

